- Home
- WOLF vs JANX Comparison
WOLF vs JANX Comparison
Compare WOLF & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WOLF | JANX |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 975.7M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WOLF | JANX |
|---|---|---|
| Price | $31.55 | $16.15 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 4 | 13 |
| Target Price | $14.33 | ★ $47.00 |
| AVG Volume (30 Days) | ★ 4.0M | 688.7K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,385,982,000.00 | $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.43 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $1.16 | $12.12 |
| 52 Week High | $80.82 | $35.34 |
Technical Indicators
Market Signals| Indicator | WOLF | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 50.47 | 53.93 |
| Support Level | $15.86 | $13.13 |
| Resistance Level | $60.25 | $16.68 |
| Average True Range (ATR) | 2.64 | 0.65 |
| MACD | 1.49 | 0.03 |
| Stochastic Oscillator | 82.85 | 67.55 |
Price Performance
Historical ComparisonAbout WOLF Wolfspeed Inc.
Wolfspeed Inc develops and manufactures semiconductor technologies based on silicon carbide (SiC) for power electronics applications. Its product portfolio includes SiC MOSFETs, Schottky diodes, and power modules used in power electronics applications. The company also provides reference designs, evaluation kits, and gate driver boards to support the development and integration of its SiC products across industries such as electric vehicles, renewable energy, and industrial systems.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.